# DeuterOncology NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deuteroncology

- Industry: Biotechnology
- Headquarters: Liege, Belgium
- Website: www.deuteroncology.com
- Total disclosed funding: $5.8M
- Latest round: Series A (Jan 2, 2023)
- Investors on record: 3

## About

Based in Gell, Belgium, and founded in 2020, DeuterOncology NV develops DO-2, a novel MET and RAS pathway inhibitor. The company was founded by Dr. Timothy Perera. In February 2021, the company raised its latest Venture funding from Newton Biocapital.

The company is focusing on the development of a dual MET and RAS pathway inhibitor for targeted cancer therapies. The company's solution, which overcomes resistance to MET inhibitors, can be used in monotherapy and combination therapy setting for cancer patients.

## Funding rounds

- Series A, Jan 2, 2023, $5.8M — Noshaq, Newton Biocapital Partners, Investsud

## Investors

- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series A
- Investsud — Series A